Evidence map›Paper›PMID 32291102›Full record

ArticleVaccine2020

Ebola vaccine? Family first! Evidence from using a brief measure on Ebola vaccine demand in a national household survey during the outbreak in Sierra Leone.

Mohamed F Jalloh, Aaron S Wallace, Rebecca E Bunnell, Rosalind J Carter, John T Redd, Sophia A Nur, Zangin Zeebari, Anna Mia Ekström, Helena Nordenstedt

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Mohamed F JallohGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, USA; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden. Electronic address: mjalloh@cdc.gov.
Aaron S WallaceGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, USA.
Rebecca E BunnellDivision of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, USA.
Rosalind J CarterGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, USA.
John T ReddCenter for Public Health Preparedness and Response, Centers for Disease Control and Prevention, Atlanta, USA.
Sophia A NurDivision of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, USA.
Zangin ZeebariDepartment of Global Public Health, Karolinska Institutet, Stockholm, Sweden; Jönköping International Business School, Jönköping, Sweden.
Anna Mia EkströmDepartment of Global Public Health, Karolinska Institutet, Stockholm, Sweden; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Helena NordenstedtDepartment of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Centers for Disease Control and Prevention · USJönköping University · SEKarolinska Institutet · SEKarolinska University Hospital · SE

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundVaccination against Ebolavirus is an emerging public health tool during Ebola Virus Disease outbreaks. We examined demand issues related to deployment of Ebolavirus vaccine during the 2014-2015 outbreak in Sierra Leone.

methodsA cluster survey was administered to a population-based sample in December 2014 (N = 3540), before any Ebola vaccine was available to the general public in Sierra Leone. Ebola vaccine demand was captured in this survey by three Likert-scale items that were used to develop a composite score and dichotomized into a binary outcome to define high demand. A multilevel logistic regression model was fitted to assess the associations between perceptions of who should be first to receive an Ebola vaccine and the expression of high demand for an Ebola vaccine.

resultsThe largest proportion of respondents reported that health workers (35.1%) or their own families (29.5%) should receive the vaccine first if it became available, rather than politicians (13.8%), vaccination teams (9.8%), or people in high risk areas (8.2%). High demand for an Ebola vaccine was expressed by 74.2% of respondents nationally. The odds of expressing high demand were 13 times greater among those who said they or their families should be the first to take the vaccine compared to those who said politicians should be the first recipients (adjusted odds ratio [aOR] 13.0 [95% confidence interval [CI] 7.8-21.6]). The ultra-brief measure of the Ebola vaccine demand demonstrated acceptable scale reliability (Cronbach's α = 0.79) and construct validity (single-factor loadings > 0.50).

conclusionPerceptions of who should be the first to get the vaccine was associated with high demand for Ebola vaccine around the peak of the outbreak in Sierra Leone. Using an ultra-brief measure of Ebola vaccine demand is a feasible solution in outbreak settings and can help inform development of future rapid assessment tools.

Indexed as

Hemorrhagic Fever, EbolaDisease OutbreaksEbola VaccinesEbolavirusHealth ResourcesHumansReproducibility of ResultsSierra LeoneSurveys and QuestionnairesVaccinationEbola VaccinesAcceptanceDemandEbolaMeasureReliabilityScaleSierra LeoneVaccineValidity

Identifiers

PMID32291102
PMCPMC10831169
OpenAlexW3015909713

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.